Chembio Diagnostics Inc  

(Public, NASDAQ:CEMI)   Watch this stock  
Find more results for CEMI
+0.09 (1.28%)
May 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.10 - 7.22
52 week 3.33 - 7.39
Open 7.15
Vol / Avg. 16,489.00/34,138.00
Mkt cap 68.52M
P/E     -
Div/yield     -
EPS -0.25
Shares 9.65M
Beta 1.04
Inst. own 17%
May 5, 2016
Q1 2016 Chembio Diagnostics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 8, 2016
Q4 2015 Chembio Diagnostics Inc Earnings Call
Mar 8, 2016
Q4 2015 Chembio Diagnostics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -14.68% -9.88%
Operating margin -27.18% -14.65%
EBITD margin - -8.99%
Return on average assets -11.93% -10.46%
Return on average equity -14.50% -12.82%
Employees 155 -
CDP Score - -


3661 Horseblock Rd
MEDFORD, NY 11763-2215
United States - Map
+1-631-9241135 (Phone)
+1-775-8849383 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.

Officers and directors

John J. Sperzel III President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Richard J. Larkin Chief Financial Officer
Age: 58
Bio & Compensation  - Reuters
Sharon Klugewicz Chief Operating Officer
Age: 47
Bio & Compensation  - Reuters
Javan Esfandiari Chief Science and Technology Officer
Age: 48
Bio & Compensation  - Reuters
Tom Ippolito Vice President - Regulatory Affairs, Quality Assurance and Quality Control
Age: 52
Bio & Compensation  - Reuters
Paul Lambotte Ph.D. Vice President - Product Development
Age: 63
Bio & Compensation  - Reuters
Michael K. Steele Vice President - Business Development, Sales and Marketing
Age: 48
Bio & Compensation  - Reuters
Katherine L. Davis Non-Executive Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Barbara A. DeBuono M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Peter T. Kissinger Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters